# Telotristat etiprate

Cat. No.:	HY-13055	
CAS No.:	1137608-69-5	
Molecular Formula:	$C_{36}H_{35}CIF_{3}N_{7}O_{6}$	çı
Molecular Weight:	754.15	
Target:	Tryptophan Hydroxylase	F F F G G G G G G G G G G G G G G G G G
Pathway:	Metabolic Enzyme/Protease	0
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C 6 months: -20°C 1 month (sealed storage, away from moisture)	

## SOLVENT & SOLUBILITY

In Vitro	DMSO : 200 mg/mL (265.20 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg	
		1 mM	1.3260 mL	6.6300 mL	13.2600 mL	
		5 mM	0.2652 mL	1.3260 mL	2.6520 mL	
		10 mM	0.1326 mL	0.6630 mL	1.3260 mL	
	Please refer to the so	lubility information to select the ap	propriate solvent.			
In Vivo	<ol> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 40% PEG300 &gt;&gt; 5% Tween-80 &gt;&gt; 45% saline Solubility: ≥ 10 mg/mL (13.26 mM); Clear solution</li> <li>Add each act was been as a 10% DMSO as 20% area it.</li> </ol>					
	Solubility: $\geq$ 10 mg/mL (13.26 mM); Clear solution					

BIOLOGICAL ACTIVITY				
Description	Telotristat etiprate (LX1606 Hippurate) is a novel, orally-delivered inhibitor of tryptophan hydroxylase that reduces serotonin production.			
In Vivo	Telotristat ethyl (15, 50, 150, 300 mg/kg, po, qd) reduces serotonin content in the periphery, but not in the brain of the mice. Telotristat ethyl (200 mg/kg po, qd) prevents the increase in blood neutrophil counts that is observed after TNBS challenge, provides significant protection in a mouse model of inflammatory bowel disease. Telotristat ethyl (200 mg/kg po, qd) protects the mouse IBD model confirmed by histopathology evaluation <sup>[1]</sup> . Telotristat ethyl (15, 50, 150, 300 mg/kg) depletes 5-HT from the jejunum but not the brain. But Telotristat ethyl (200 mg/kg, p.o.) does not deplete enteric neuronal serotonin (5-HT), or alter constitutive gastrointestinal motility in mice. Telotristat ethyl (200 mg/kg) alleviates the severity of trinitrobenzene sulfonic acid (TNBS)-induced colitis <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			

# Product Data Sheet

C H O OH



### PROTOCOL

# Animal<br/>Administration [2]For studies of the effects of peripheral TPH inhibitors on gut and brain 5-HT concentrations, LP-920540 is formulated in 0.1%<br/>Tween 80 in 0.25% methylcellulose and administered to mice once daily via oral gavage at 10 mL/kg for 4 consecutive days.<br/>Telotristat ethyl is formulated in 15% cyclodextrin (Captisol<sup>TM</sup>, pH 3-4) or 0.25% methylcellulose and given to mice once<br/>daily via oral gavage at 10 mL/kg for 4 consecutive days. Whole brain, jejunum and colon (mesentery fat removed, gut lumen<br/>opened and blotted dry) are collected, snap frozen, and stored at -80°C for future. LP-920540, Telotristat ethyl, LP-778914,<br/>LP-778920 and vehicle control are also formulated with 0.5% methycellulose at appropriate doses in coded vials. The<br/>contents of the coded vials are given by oral gavage in amounts determined by the weights of the recipient mice. After the<br/>experiments, results are analyzed.<br/>MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### **CUSTOMER VALIDATION**

• Nutrients. 2022, 14(1), 117.

See more customer validations on www.MedChemExpress.com

### REFERENCES

[1]. Tamas Oravecz, et al. LX1606 (aka LX1032), a Novel Inhibitor of Serotonin Synthesis, Alleviates Development of Inflammatory Bowel Disease in a Preclinical Model.

[2]. Margolis, K.G., et al., Pharmacological reduction of mucosal but not neuronal serotonin opposes inflammation in mouse intestine. Gut, 2013.

Caution: Product has not been fully validated for medical applications. For research use only.